Irene M. Ghobrial, MD, of Dana-Farber Cancer Institute, talks about PROMISE—her screening study for people at high-risk of developing precursor conditions of multiple myeloma—and how this and other trials have been altered in the wake of the pandemic, as well as what might be considered a silver lining to the crisis. Filmed March 30, 2020.
During the COVID-19 pandemic, do you suggest delaying upfront autologous transplant for patients with multiple myeloma?
Recorded April 24,...
Derek Raghavan, MD, PhD, of the Levine Cancer Institute in Charlotte, and a member of The ASCO Post Editorial Board, discusses the ways in which COVID-19 has affecte...
Syed A. Abutalib, MD, of Cancer Treatment Centers of America, talks with Miguel-Angel Perales, MD, of Memorial Sloan Kettering Cancer Center, about the chall...
Karen E. Knudsen, PhD, MBA, Director of the Sidney Kimmel Cancer Center, talks about what she and her staff have encountered during the COVID-19 crisis and how they and their...
During the COVID-19 pandemic, would you still recommend immediate upfront autologous transplant in patients with T-cell non-Hodgkin lymphoma?
Recorded April 21, 2020.
